V
Viridian Therapeutics D
D
VRDN
17.230
USD
-0.45
(-2.55%)
مغلق
حجم التداول
0
الربح لكل سهم
-4
العائد الربحي
-
P/E
-5
حجم السوق
1,902,668,961
المقالات
العنوان: Viridian Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibodytargeting IGF-1R intravenously administered for the treatment of TED.